Company: MDCXW
Filing Date: 2025-09-11
Form Type: DRS
Source: 0001062993-25-015568
Chunk: 13

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-11
Form: DRS
Chunk 13
---
the "Warrant Inducement Agreement"), pursuant to which Armistice agreed to exercise existing warrants to purchase up to 1,340,000 of the Company's common shares issued on March 10, 2025 with an exercise price of $2.80 per Common Share (the "Regulation A Warrants"), in consideration for receiving the 2,680,000 warrants to purchase common shares with an exercise price of $3.75 (the "Private Warrants"). In accordance with the Warrant Inducement Agreement, Armistice exercised its Regulation A Warrants for cash, for gross proceeds of $3,752,000 to the Company.

<div align='center'>4</div>

| CONFIDENTIAL TREATMENT REQUESTED BY MEDICUS PHARMA LTD. 
 PURSUANT TO 17 C.F.R. SECTION 200.83                    |

Debt Financing with the Selling Shareholder

On May 2, 2025, the Company entered into a securities purchase agreement (the "Purchase Agreement") with Yorkville (as defined herein) in connection with the issuance and sale by the Company of debentures (the "Debentures") issuable in an aggregate principal amount of up to $5,000,000. Under the Purchase Agreement, Yorkville purchased and the Company issued three Debentures totaling $5,000,000 in the aggregate, for gross proceeds of $4,500,000, following the 90% issuance price. The Debentures are guaranteed by each of the Company's subsidiaries pursuant to a global guaranty agreement (the "Guaranty"). Interest will accrue on the outstanding principal amount of each Debenture at an annual rate of 8.00%, subject to a potential increase to 18.00% per annum upon the occurrence of certain events of default. The Debentures will mature on February 2, 2026. The foregoing descriptions of the Purchase Agreement, Guaranty and Debentures do not purport to be complete and are qualified in their entirety by reference to the full text of such documents, and with respect to the Debentures, a form thereof, which are filed as exhibits hereto and are incorporated herein by reference. As of the date hereof the Company has repaid more than half of the outstanding principal amount of the Debentures.

June 2025 Public Offering

On June 2, 2025, the Company closed a public offering of 2,260